Abstract: The present invention relates to 14- or 15-membered macrolides substituted at the 4? position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

Abstract: A method of inhibiting MetRS activity comprises administering to a patient in need thereof a MetRS inhibiting effective amount of a compound of the formula (I). A method of treating a resistant or multiply-resistant E. faecalis infection, a resistant or multiply-resistant S. aureus infection, and/or a resistant or multiply-resistant S. epidermidis infection comprises administering to a patient in need thereof an antibacterially effective amount of a compound of the formula (I).

Abstract: The present invention relates to 14- or 15-membered macrolides substituted at the 4? position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

Abstract: Compounds of formula (I): are inhibitors of bacterial methionyl tRNA synthetase and are of use in treating bacterial infections.

Abstract: A substrate to be cut and/or scored is pre-printed with graphics, at least first and second registration marks, and optional encoded-to-print instructions, bar-encoded data, as well as ordinary graphics. The registration marks are sensed as the substrate is automatically transported to a cutting table station that defines a cutting reference plane. Sensed detection of location of the registration marks relative to the reference plane enable the cutting plan for the substrate to be amended for precise location of the graphics on the substrate relative to the reference plane. Automated cutting according to the amended cutting plan occurs. As the registration marks were printed simultaneously with and in known relationship to the graphics, the cut line will be precise relative to the graphics. Machine readable encoded-to-print instructions optionally printed on the substrate can further amend the cutting plan.

Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

Abstract: Novel substituted thiophenes that are inhibitors of bacterial methionyl t-RNA synthetase (MRS) are disclosed. Also disclosed are method for their preparation and their use in therapy as anti-bacterial agents.

Abstract: Novel substituted thiophenes that are inhibitors of bacterial methionyl t-RNA synthetase (MRS) are disclosed. Also disclosed are method for their preparation and their use in therapy as anti-bacterial agents.

Abstract: Compounds of formula (I): are inhibitors of bacterial methionyl tRNA synthetase and are of use in treating bacterial infections.

Abstract: Compounds of formula (I): are inhibitors of bacterial methionyl tRNA synthetase and are of use in treating bacterial infections.

Abstract: A substrate to be cut and/or scored is pre-printed with graphics, at least first and second registration marks, and optional encoded-to-print instructions, bar-encoded data, as well as ordinary graphics. The registration marks are sensed as the substrate is automatically transported to a cutting table station that defines a cutting reference plane. Sensed detection of location of the registration marks relative to the reference plane enable the cutting plan for the substrate to be amended for precise location of the graphics on the substrate relative to the reference plane. Automated cutting according to the amended cutting plan occurs. As the registration marks were printed simultaneously with and in known relationship to the graphics, the cut line will be precise relative to the graphics. Machine readable encoded-to-print instructions optionally printed on the substrate can further amend the cutting plan.

Abstract: Novel substituted thiophenes that are inhibitors of bacterial methionyl t-RNA synthetase (MRS) are disclosed. Also disclosed are method for their preparation and their use in therapy as anti-bacterial agents.

Abstract: Compounds of formula (I): 1

Abstract: A compound of formula (I): ##STR1## or a pharmaceutically acceptable acid addition salt and/or a pharmaceutically acceptable solvate thereof, wherein A represents a residue of a benzene ring optionally having up to four substituents selected from the group consisting of halogen, C.sub.1-6 alkyl aNd C.sub.1-6 alkoxy; R.sup.1 and R.sup.2 each independently represent a hydrogen atom or a C.sub.1-6 alkyl group; X represents a bond or a moiety CHR.sup.1 wherein R.sup.1 is as defined above; and Z represents O, NH or S.

Abstract: Compounds of formula (I): ##STR1## or a pharmaceutically acceptable salt thereof,in whichR.sup.1 is hydrogen, halogen, or trifluoromethyl,R.sup.2 is hydrogen or halogen,R.sup.3 is hydroxyl, C.sub.1-6 alkoxy or ##STR2## where R.sup.8 and R.sup.9 are each hydrogen or C.sub.1-6 alkyl; R.sup.4 is hydrogen or C.sub.1-6 alkyl; R.sup.5 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkyl optionally substituted by hydroxy; cyano, C.sub.1-6 alkenyl or C.sub.1-6 alkynyl optionally substituted by carboxy or esters and amides thereof, phenyl, C.sub.1-6 alkyl phenyl or a group ##STR3## wherein R.sup.12 and R.sup.13 are each hydrogen or C.sub.1-6 alkyl or together, along with the nitrogen to which they are attached, form a 5- or 6-membered ring and m is 1 or 2;R.sup.6 is hydrogen or methyl:R.sup.7 is --O(CH.sub.2).sub.a CO.sub.2 H, --O(CH.sub.2).sub.b M, --CO.sub.2 H; or amide thereof in whicha is an integer from 1 to 6,b is an integer from 2 to 7, andM is hydroxy, C.sub.1-6 alkoxy or ##STR4## in which R.sup.10 and R.sup.

Abstract: Compounds of formula (I): ##STR1## or a pharmaceutically acceptable salt, ester or amide thereof, wherein: Ar is benzofuran-2-yl, or phenyl optionally substituted by groups R.sup.1 and/or R.sup.2 wherein R.sup.1 is halogen, trifluoromethyl or hydroxy and R.sup.2 is halogen;R.sup.3 is hydrogen or methyl;X is --O(CH.sub.2).sub.a CO.sub.2 H, --O(CH.sub.2)bM or --CO.sub.2 Hin whicha is an integer from 1 to 6,b is an integer from 2 to 7,M is hydroxy, C.sub.1-6 alkoxy, phenyl C.sub.1-6 alkoxy, or --NR.sup.4 R.sup.5 in which R.sup.4 and R.sup.5 are each hydrogen or C.sub.1-6 alkyl or together form a five or six membered heterocyclic ring;Y is C.sub.2-6 straight or branched alkylene, with at least two carbon atoms between the --O-- and --OH;and n is 1 or 2,having anti-obesity and/or anti-hyperglycaemic activity, processes for their preparation and their pharmaceutical use.